433 related articles for article (PubMed ID: 22490570)
21. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
Schwartzberg LS; Badarinath S; Keaton MR; Childs BH
Clin Breast Cancer; 2014 Jun; 14(3):161-8. PubMed ID: 24566467
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.
Sanna G; Fabi A; Crivellari D; Saracchini S; Battelli N; Nisticò C; Capobianco AM; Zampa G; Bottini A; Del Prete S; Simoncini E; Galli A; Matasconi M; Restuccia E; Biganzoli L
Tumori; 2014; 100(4):432-8. PubMed ID: 25296593
[TBL] [Abstract][Full Text] [Related]
23. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
[TBL] [Abstract][Full Text] [Related]
24. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
[TBL] [Abstract][Full Text] [Related]
25. [Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Hardy-Bessard AC; Delva R; Pivot X; Espié M; Dalenc F; Coulon Sfairi MA; Monnier A; Serin D; Veyret C; Lortholary A; Pavlyuk M; Kockler L; Pierga JY
Bull Cancer; 2012 Jun; 99(6):609-18. PubMed ID: 22665515
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
[TBL] [Abstract][Full Text] [Related]
28. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
29. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Untch M; Loibl S; Bischoff J; Eidtmann H; Kaufmann M; Blohmer JU; Hilfrich J; Strumberg D; Fasching PA; Kreienberg R; Tesch H; Hanusch C; Gerber B; Rezai M; Jackisch C; Huober J; Kühn T; Nekljudova V; von Minckwitz G; ;
Lancet Oncol; 2012 Feb; 13(2):135-44. PubMed ID: 22257523
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
31. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.
Zhao M; Pan X; Layman R; Lustberg MB; Mrozek E; Macrae ER; Wesolowski R; Carothers S; Puhalla S; Shapiro CL; Ramaswamy B
Invest New Drugs; 2014 Dec; 32(6):1285-94. PubMed ID: 24894652
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
34. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
35. First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.
Müller V; Ruhnke M; Hoffmann O; Grafe A; Tomé O; Fett W; Bruch HR; Sommer-Joos AK; Schneeweiss A
Breast; 2021 Dec; 60():70-77. PubMed ID: 34488065
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
[TBL] [Abstract][Full Text] [Related]
37. First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
Biganzoli L; Di Vincenzo E; Jiang Z; Lichinitser M; Shen Z; Delva R; Bogdanova N; Vivanco GL; Chen Z; Cheng Y; Just M; Espié M; Vinholes J; Hamm C; Crivellari D; Chmielowska E; Semiglazov V; Dalenc F; Smith I
Ann Oncol; 2012 Jan; 23(1):111-118. PubMed ID: 21444356
[TBL] [Abstract][Full Text] [Related]
38. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
[TBL] [Abstract][Full Text] [Related]
39. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Miles DW; Chan A; Dirix LY; Cortés J; Pivot X; Tomczak P; Delozier T; Sohn JH; Provencher L; Puglisi F; Harbeck N; Steger GG; Schneeweiss A; Wardley AM; Chlistalla A; Romieu G
J Clin Oncol; 2010 Jul; 28(20):3239-47. PubMed ID: 20498403
[TBL] [Abstract][Full Text] [Related]
40. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Bisagni G; Musolino A; Panebianco M; De Matteis A; Nuzzo F; Ardizzoni A; Gori S; Gamucci T; Passalacqua R; Gnoni R; Moretti G; Boni C
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1051-7. PubMed ID: 23377310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
